Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is benefiting from its expansion into full-risk contracts and its conservative approach to reserving and managing patient utilization, resulting in strong cash flow and positive margins. The company is on track to surpass its synergy targets and remains well-positioned for future growth in its Medicare and Medicaid markets. Its strong Q1 performance and favorable outlook for 2027 contribute to a positive outlook for the company's stock.

Bears say

Astrana Health is currently going through a period of transition and integration, which may cause disruption and result in underperformance. Additionally, the company is facing execution risks associated with its recent acquisition of Prospect Health, as it works to align operations, risk contract performance, and provider networks. The company also faces potential challenges related to its high valuation and potential volatility in the healthcare industry, including increased utilization levels and delays in realizing savings from care-management initiatives. These factors may negatively impact the company's financial results, creating downside risk to its earnings and cash flow in the near term.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.